Compare LYTS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYTS | REPL |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.9M | 692.8M |
| IPO Year | 1994 | 2018 |
| Metric | LYTS | REPL |
|---|---|---|
| Price | $21.34 | $7.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $27.50 | $11.13 |
| AVG Volume (30 Days) | 132.3K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $573,377,000.00 | N/A |
| Revenue This Year | $8.01 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | $48.79 | ★ N/A |
| Revenue Growth | ★ 22.09 | N/A |
| 52 Week Low | $13.77 | $2.68 |
| 52 Week High | $24.75 | $13.24 |
| Indicator | LYTS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 45.57 |
| Support Level | $17.84 | $6.90 |
| Resistance Level | $23.99 | $8.07 |
| Average True Range (ATR) | 0.93 | 0.55 |
| MACD | -0.22 | 0.04 |
| Stochastic Oscillator | 31.85 | 26.88 |
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.